The tweet was deleted by the author.
But we saved everything 🙂.
Arvinas is presenting new research data on its PROTAC LRRK2 degraders at the Alzheimer Association International Conference (AAIC26) in London.
The company is sharing advancements in the development of these novel compounds, which target LRRK2, a key protein implicated in neurodegenerative diseases. Attending AAIC26 provides Arvinas with an opportunity to engage with the scientific community and highlight early-stage progress toward potential therapeutic solutions for conditions such as Alzheimer disease. Further information is available via the official conference website.
View post on X Loading...
Earlier this summer, Arvinas hosted a community event for employees featuring lawn games and a painting activity with Hospital Art. The initiative aimed to foster engagement among staff members. This follows the company's ongoing efforts to advance its research and development programs.